Electrophysiological study as a method for risk stratification of sudden death in Brugada syndrome
DOI:
https://doi.org/10.55204/trc.v3i1.e168Keywords:
Arrhythmias, Cardiac, Brugada Syndrome, Death, Electrophysiologic TechniquesAbstract
Introduction: electrophysiological study has been used as a diagnostic method and predictor of sudden cardiac death in patients with Brugada syndrome, allowing stratification of the risk of developing malignant ventricular arrhythmias. However, in recent years, its usefulness has been questioned. Objective: to describe the electrophysiological study as a method for stratifying the risk of sudden death in Brugada syndrome. Methods: an electronic search was performed in databases such as: Pubmed, ScienceDirect and Scielo in a period from January 2018 to February 2023, keywords such as; Cardiac Arrhythmias, Brugada Syndrome, Electrophysiologic Techniques, Sudden Death were also used, according to bibliographic descriptors DeCS and MeSH in addition to bilean operators such as "AND, OR and NOT". Results: a total of 14 studies were identified, most of them reported the electrophysiological study as a good predictor of risk of sudden cardiac death, the main findings were: right bundle branch block and ST segment deviation in lead V1, QT prolongation, type 1 ECG pattern, presence of a prolonged Tpeak-Tend QRS interval with ventricular effective refractory period <200, and other arrhythmic events that in patients with Brugada Syndrome may increase the risk of sudden death. Conclusion: electrophysiological study in patients diagnosed with Brugada syndrome is a good marker of long-term cardiac events and may even be useful for predicting a greater association with risk of sudden death.Downloads
References
Pappone C, Ciconte G, Manguso F, Vicedomini G, Mecarocci V, Conti M, et al. Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome. J Am Coll Cardiol. 17 de abril de 2018;71(15):1631-46.
Honarbakhsh S, Providencia R, Garcia-Hernandez J, Martin CA, Hunter RJ, Lim WY, et al. A Primary Prevention Clinical Risk Score Model for Patients With Brugada Syndrome (BRUGADA-RISK). JACC Clin Electrophysiol. febrero de 2021;7(2):210-22.
Patel N, Kalra R, Doshi R, Bajaj NS, Arora G, Arora P. Trends and Cost of Heart Transplantation and Left Ventricular Assist Devices: Impact of Proposed Federal Cuts. JACC Heart Fail. mayo de 2018;6(5):424-32.
Wald R, Dorian P, Harel Z. Benefits and Risks of Anticoagulation in Dialysis Patients With Nonvalvular Atrial Fibrillation: Navigating Through Darkness. J Am Coll Cardiol. 28 de enero de 2020;75(3):286-8.
Delise P. Risk stratification in Brugada syndrome: the challenge of the grey zone. Eur Heart J. 1 de mayo de 2021;42(17):1696-7.
Rodríguez-Mañero M, Baluja A, Hernández J, Muñoz C, Calvo D, Fernández-Armenta J, et al. Validación de escalas multiparamétricas de predicción de riesgo de muerte súbita en pacientes con síndrome de Brugada y estudio electrofisiológico. Revista Española de Cardiología. 1 de julio de 2022;75(7):559-67.
Asada S, Morita H, Watanabe A, Nakagawa K, Nagase S, Miyamoto M, et al. Indication and prognostic significance of programmed ventricular stimulation in asymptomatic patients with Brugada syndrome. EP Europace. 1 de junio de 2020;22(6):972-9.
Hernandez-Ojeda J, Arbelo E, Jorda P, Borras R, Campuzano O, Sarquella-Brugada G, et al. The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. Am Heart J. febrero de 2020;220:213-23.
Lee S, Li KHC, Zhou J, Leung KSK, Lai RWC, Li G, et al. Outcomes in Brugada Syndrome Patients With Implantable Cardioverter-Defibrillators: Insights From the SGLT2 Registry. Front Physiol. 10 de marzo de 2020;11:204.
Romero J, Li DL, Avendano R, Diaz JC, Tung R, Di Biase L. Brugada Syndrome: Progress in Genetics, Risk Stratification and Management. Arrhythm Electrophysiol Rev. marzo de 2019;8(1):19-27.
Asvestas D, Tse G, Baranchuk A, Bazoukis G, Liu T, Saplaouras A, et al. High risk electrocardiographic markers in Brugada syndrome. Int J Cardiol Heart Vasc. marzo de 2018;18:58-64.
Russo V, Pafundi PC, Caturano A, Dendramis G, Ghidini AO, Santobuono VE, et al. Electrophysiological Study Prognostic Value and Long-Term Outcome in Drug-Induced Type 1 Brugada Syndrome. JACC: Clinical Electrophysiology. octubre de 2021;7(10):1264-73.
Giustetto C, Cerrato N, Ruffino E, Gribaudo E, Scrocco C, Barbonaglia L, et al. Etiological diagnosis, prognostic significance and role of electrophysiological study in patients with Brugada ECG and syncope. Int J Cardiol. 15 de agosto de 2017;241:188-93.
Hosseini K, Jahangiri M, Vasheghani Farahani A. Performance of electrophysiologic study in an asymptomatic patient with type 2 intermittent Brugada syndrome: To do or not to do. Caspian J Intern Med. 2018;9(1):92-5.
Shinohara T, Takagi M, Kamakura T, Sekiguchi Y, Yokoyama Y, Aihara N, et al. Risk stratification in asymptomatic patients with Brugada syndrome: Utility of multiple risk factor combination rather than programmed electrical stimulation. J Cardiovasc Electrophysiol. febrero de 2021;32(2):507-14.
Darar C, Mohammed EA, Mohammed B, Noha EO, Zakaria B. Risk stratification of sudden cardiac death in Brugada syndrome: an updated review of literature. The Egyptian Heart Journal. 11 de abril de 2022;74(1):25.
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2 de octubre de 2018;72(14):1677-749.
Nagase S. Risk stratification in Brugada syndrome - Significance of ECG and depolarization abnormality. Int J Cardiol. 15 de marzo de 2020;303:56-7.
Eckardt L. [Brugada syndrome : Risk stratification and prevention of sudden cardiac death]. Herzschrittmacherther Elektrophysiol. marzo de 2020;31(1):39-47.
Rodriguez, Lopez, Navia, Mora, Dueñas. Síndrome de Brugada. Aspectos fisiopatológicos, clínicos y su asociación con enfermedades infecciosas. 2019;32(034-95):3.
Aziz HM, Zarzecki MP, Garcia-Zamora S, Kim MS, Bijak P, Tse G, et al. Pathogenesis and Management of Brugada Syndrome: Recent Advances and Protocol for Umbrella Reviews of Meta-Analyses in Major Arrhythmic Events Risk Stratification. Journal of Clinical Medicine. enero de 2022;11(7):1912.
Iacopino S, Chierchia GB, Sorrenti P, Pesce F, Colella J, Fabiano G, et al. dST-Tiso Interval, a Novel Electrocardiographic Marker of Ventricular Arrhythmia Inducibility in Individuals With Ajmaline-Induced Brugada Type I Pattern. Am J Cardiol. 15 de noviembre de 2021;159:94-9.
Popa IP, Șerban DN, Mărănducă MA, Șerban IL, Tamba BI, Tudorancea I. Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification. International Journal of Molecular Sciences. enero de 2023;24(4):3328.
London B. Letter by London Regarding Article, “Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome”. Circulation. 2 de abril de 2019;139(14):1758-9.
Long-term prognosis of patients with Brugada syndrome and an implanted cardioverter-defibrillator | Revista Portuguesa de Cardiologia (English edition) [Internet]. [citado 12 de marzo de 2023]. Disponible en: https://www.revportcardiol.org/en-long-term-prognosis-patients-with-brugada-syndrome-an-implanted-articulo-S0870255115001237
Pérez-Riera AR, Mendes JET, Silva FF da, Yanowitz F, Abreu LC de, Figueiredo JL, et al. Brugada syndrome: current concepts and genetic background. Journal of Human Growth and Development. 28 de abril de 2021;31(1):152-76.
Li KHC, Lee S, Yin C, Liu T, Ngarmukos T, Conte G, et al. Brugada syndrome: A comprehensive review of pathophysiological mechanisms and risk stratification strategies. Int J Cardiol Heart Vasc. febrero de 2020;26:100468.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Clarisa Isabel Calderón Centeno, María Daniela Carpio Toro
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. They only give to the magazine Tesla Revista Científica the right to the first publication of this. Since Tesla Revista Científica is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself. Tesla Revista Científica undertakes not to make commercial use of the texts it receives and/or publishes.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
